Skip to content
10-Q

Quarterly Report

OnKure Therapeutics, Inc. OKUR

0000950170-25-063970

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q1 2025 · Mar 31, 2025 $96.66M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $110.76M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.79M
Current Liabilities Q1 2025 · Dec 31, 2024 $10.53M
Total Liabilities Q1 2025 · Mar 31, 2025 $9.23M
Total Liabilities Q1 2025 · Dec 31, 2024 $11.08M
Current Assets Q1 2025 · Mar 31, 2025 $98.17M
Current Assets Q1 2025 · Dec 31, 2024 $113M
Total Assets Q1 2025 · Mar 31, 2025 $99.88M
Total Assets Q1 2025 · Dec 31, 2024 $114.91M
Net Income Q1 2025 · Dec 31, 2024 −$17.44M
Net Income Q1 2025 · Sep 30, 2024 −$11.56M
Net Income Q1 2025 · Jun 30, 2024 −$14.14M
Net Income restated Q1 2025 · Mar 31, 2024 −$9.54M
Stockholders Equity Q1 2025 · Sep 30, 2024 −$135.05M
Stockholders Equity Q1 2025 · Jun 30, 2024 −$123.58M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 −$111.26M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$101.84M
Shares Diluted restated Q1 2025 · Mar 31, 2024 314.02K sh
Capex Q1 2025 · Mar 31, 2024 $9K
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$10.63M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$30.37
Eps Basic restated Q1 2025 · Mar 31, 2024 −$30.37
Sga Expense restated Q1 2025 · Mar 31, 2024 $1.27M
Rd Expense restated Q1 2025 · Mar 31, 2024 $8.57M
Operating Income restated Q1 2025 · Mar 31, 2024 −$9.83M